Table 1.

Multivariate Cox regression model results including age, treatment type (chemotherapy, bevacizumab, or cabozantinib), and continuous measures of baseline contrast enhancing lesion volume (enhancement plus central necrosis)

Variable	Coefficient	Hazard Ratio	95% CI	P
Age	0.0057 ± 0.0042	1.0058	(0.9975–1.0141)	.2970
Treatment(chemotherapy, bevacizumab, cabozantinib)	0.0546 ± 0.0524	1.0561	(0.9531–1.1702)	.1720
Pretreatment Volume (continuous)(cubic centimeters)	0.0158 ± 0.0021	1.0159	(1.0117–1.0201)	<.0001